Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis

Published:2020-08-27 Issue:11 Volume:23 Page:1514-1525
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Alten Rieke¹^ORCID,Markland Colin²^ORCID,Boyce Malcolm³^ORCID,Kawakami Kazuki⁴^ORCID,Muniz Rafael⁵^ORCID,Genovese Mark C.⁶^ORCID

Affiliation:

1. University Medicine Berlin Berlin Germany

2. NDA Group Leatherhead UK

3. Hammersmith Medicines Research London UK

4. Fujifilm Kyowa Kirin Biologics Tokyo Japan

5. Mylan Inc Canonsburg PA USA

6. Stanford University Palo Alto CA USA

Funder

Fujifilm Corporation

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.13951

Reference23 articles.

1. Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

2. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)

3. US Food and Drug Administration.Biosimilar and interchangeable products.2017.www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm. Accessed October 17 2018

4. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects

5. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers;International Journal of Pharmaceutics: X;2024-06

2. Maximizing the success of biosimilar implementation;Nature Reviews Rheumatology;2023-10-30

3. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis;Scientific Reports;2023-08-22

4. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis;JAMA Network Open;2023-05-26

5. Genetic polymorphisms of FcGR2B and adalimumab effectiveness in Colombian patients with rheumatoid arthritis. Cases-controls study;2022-09-21